Evaluating blood tests for breast cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses the effectiveness of liquid biopsy (LBx) in diagnosing breast cancer by comparing its results with traditional mammography findings. The primary objectives are to determine the sensitivity and specificity of LBx in various patient cohorts. Participants will provide blood samples and have their medical records reviewed to evaluate the correlation between LBx results and breast cancer diagnoses. The study aims to enhance diagnostic accuracy and potentially improve patient outcomes in breast cancer detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* Women

  * Age ≥ 18 years.
  * Screening Mammography Cohort: Patients who were referred for screening mammography and had mammography performed within 6 months prior to blood draw or will be undergoing mammography within 6 months after blood draw. Patient must not have personal history of breast cancer, history of breast biopsy or prior abnormal mammography findings are allowed. OR
  * Abnormal Screening Cohort: Patient who has had mammography that revealed abnormal results (BIRADS 3, 4, 5) or abnormal MRI results requiring further testing (additional imaging modality or biopsy). Patients must not have a history of breast cancer, history of breast biopsy, or prior abnormal mammography findings are allowed. The blood draw must occur in the time between the abnormal mammography and start of definitive treatment (surgery or neoadjuvant chemotherapy). Patients who have already undergone surgery/excisional biopsy due to abnormal mammography findings are not eligible. OR
  * New Beast Cancer Cohort: Patients with new biopsy proven diagnosis of breast cancer (invasive breast cancer or DCIS) within 60 days of blood draw who has not started any cancer directed therapy, including surgery, radiation, hormonal therapy or chemotherapy. Any breast cancer type patients at any stage are eligible. OR
  * Remission Breast Cancer Cohort: Patients with personal history of localized breast cancer (stage 1, 2, 3) that has been previously treated with cancer directed therapy, such as surgery, chemotherapy, radiation and/or hormonal therapy who has been in completed remission. Patients must complete their surgery, adjuvant chemotherapy and/or radiation therapy prior to enrollment. The blood draw must occur at least 90 days after completion of the specified treatment modalities. Patients on adjuvant hormonal therapy are eligible to enroll (those who are treated with adjuvant hormonal therapy in combination with CDK4/6 inhibitor must complete CDK4/6 inhibitor therapy prior to enrollment).

Exclusion Criteria:

* \* Patients unable to give informed consent

  * Patients who have received blood transfusion with 14 days prior to study blood draw
  * Patients who had a heart attack, stroke, or pulmonary embolism within 3 months to study blood draw
  * Excisional breast biopsy in the prior 30 days. Needle biopsy of the breast is permitted

Where it's running

• Keck Medicine of USC Koreatown
  Los Angeles, California, United States Recruiting
• Los Angeles General Medical Center
  Los Angeles, California, United States Recruiting
• USC / Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting
• USC Norris Oncology/Hematology-Newport Beach
  Newport Beach, California, United States Recruiting

Study contacts

• Principal investigator: Anastasia Martynova, MD — University of Southern California
• Study coordinator: Kimberly Arieli, RN
• Email: Kimberly.Arieli@med.usc.edu
• Phone: 323-865-0451

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mobile health navigation to improve breast cancer screening in Kenyan women

  This study tests m-Health patient navigation tools to help women in Kenya access breast cancer screening and early detection services.

  Recruiting Emory University · Atlanta, Georgia · NCT07764796

• Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression

  This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.

  Recruiting at 11 sites City of Hope Medical Center · Arcadia, California and 10 other locations · NCT07741968

• Environmental exposure checks in high-risk and early-onset breast cancer care

  This study tests how patients and providers feel about using environmental exposure risk data in breast cancer care for women at average/high risk or with early-onset breast cancer.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07690852

• CSF sample collection from people with metastatic breast cancer to see brain metastasis risk

  This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619534

• Body composition and outcomes after breast reconstruction

  This study will see if detailed body composition measurements can help predict complications after mastectomy with immediate breast reconstruction in adult women.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07546331

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.